Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85691 | 1.00 | ALK (0.31) | ALKHCRTR2 | |
| SCHEMBL14491697 | 0.84 | HCRTR2 (0.30) | HCRTR2 | |
| SCHEMBL14491686 | 0.84 | HCRTR2 (0.30) | HCRTR2 | |
| SCHEMBL14254431 | 0.80 | HCRTR2 (0.31) | HCRTR2 | |
| SCHEMBL14254447 | 0.80 | HCRTR2 (0.31) | HCRTR2 | |
| SCHEMBL92509 | 0.80 | PLG (0.33) | — | |
| SCHEMBL92381 | 0.80 | PLG (0.33) | — | |
| SCHEMBL14592491 | 0.79 | CHRNB2 (0.37) | — | |
| SCHEMBL14592492 | 0.79 | CHRNB2 (0.37) | — | |
| SCHEMBL12674081 | 0.73 | GLB1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | ALK 1600/4885HCRTR2 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.